Get notified when VVOS files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Delisting (new) — Company received formal Nasdaq notice for failing minimum stockholders' equity requirement and faces potential delisting if unable to regain compliance.
Vivos Therapeutics receives Nasdaq delisting notice over negative stockholders' equity
Filed April 22, 2026 · Period ending April 22, 2026 · ~1 min read
Key Changes
-
high
Nasdaq notified Vivos on April 17 that its negative $1.55 million stockholders' equity fails the $2.5 million minimum requirement. Company has until June 1 to submit a compliance plan or face delisting.
Item 3.01 verify on EDGAR → -
high
Vivos raised $6.8 million in Q1 2026 through warrant exercises ($4.6M) and private placement ($2.25M), which may help restore compliance but doesn't automatically cure the deficiency.
Item 3.01 verify on EDGAR → -
medium
If Nasdaq accepts the compliance plan, Vivos could receive up to 180 days (until October 14, 2026) to regain compliance through additional financing or improved operations.
Item 3.01 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade VVOS commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify